Institutional members access full text with Ovid®

An Increased TREK-1like Potassium Current in Ventricular Myocytes During Rat Cardiac Hypertrophy

Wang, Weiping PhD; Zhang, Man MS; Li, Pingping PhD; Yuan, Hui PhD; Feng, Nan BS; Peng, Ying PhD; Wang, Ling BS; Wang, Xiaoliang PhD

Journal of Cardiovascular Pharmacology: April 2013 - Volume 61 - Issue 4 - p 302–310
doi: 10.1097/FJC.0b013e318280c5a9
Original Article

Abstract: To elucidate the expression and identify the functional changes of 2 pore domain potassium channel TREK-1 during cardiac hypertrophy in rats, left ventricular hypertrophy was induced by subcutaneous injection with isoproterenol. Western blot was used to detect the expression of TREK-1 channel protein, and inside-out and whole-cell recordings were used to record TREK-1 currents. The results showed that TREK-1 protein expression in endocardium was slightly higher than that in epicardium in control left ventricles. However, it was obviously upregulated by 89.8% during hypertrophy, 2.3-fold higher than in epicardium. Mechanical stretch, intracellular acidification, and arachidonic acid could activate a TREK-1–like current in cardiomyocytes. The slope conductances of cardiac TREK-1 and CHO/TREK-1 channels were 123 ± 7 and 113 ± 17 pS, respectively. The TREK-1 inhibitor L-3-n-butylphthalide (10 μM) reduced the currents in CHO/TREK-1 cells, normal cardiomyocytes, and hypertrophic cardiomyocytes by 48.5%, 54.3%, and 55.5%, respectively. The percentage of L-3-n-butylphthalide–inhibited outward whole-cell current in hypertrophic cardiomyocytes (23.7%) was larger than that in normal cardiomyocytes (14.2%). The percentage of chloroform-activated outward whole-cell current in hypertrophic cardiomyocytes (58.3%) was also larger than normal control (40.2%). Our results demonstrated that in hypertrophic rats, TREK-1 protein expression in endocardium was specifically increased and the ratio of TREK-1 channel current in cardiac outward currents was also enhanced. TREK-1 might balance potassium ion flow during hypertrophy and might be a potential drug target for heart protection.

State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Reprints: State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Xiaoliang Wang, PhD, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, 1 Xian Nong Tan St, Beijing 100050, China (e-mail wangxl@imm.ac.cn).

Supported by the National Natural Science Foundation of China (no. 90913019) and National Major Special Project on New Drug Innovation of China (no. 2012ZX09301002-004).

The authors report no conflicts of interest.

Received August 13, 2012

Accepted November 30, 2012

© 2013 Lippincott Williams & Wilkins, Inc.